Investigator Brochure Writing Software: Sources and Updates

Disclosure and method: Assyro publishes this guide; its first placement is our editorial recommendation. The comparison uses official product materials checked September 14, 2026. We have not run a comparative product trial. The example below is a fictional procurement exercise, with expected results you can use in a demonstration.

This guide is for a medical-writing lead choosing software for a medicinal-product investigator's brochure, working with clinical development, safety, nonclinical, regulatory, and document-control colleagues. It covers initial drafting and subsequent evidence updates. Medical-device IB requirements need a separate assessment.

A shortlist organized around the work you need done

There are two different purchases here: software that helps write an IB, and software that controls the document through review and release. Your team may need both. Establish which responsibility each product will own before comparing proposals.

These are candidates for different parts of the same task, not four demonstrated equivalents. The official pages do not identify a common software edition, build, or implementation scope. Ask vendors to put those details in the proposal.

TriloDocs is worth watching, but its current product page still places Investigator Brochure in the 2026 Q3 expansion sequence. A quarter on a roadmap is not evidence of an available IB workflow. If a vendor offers a newer release, require release documentation and a working demonstration before changing its eligibility.

What an IB update workflow has to preserve

An IB can contain statements based on different evidence periods. A new clinical summary may change a current safety statement while leaving a historical nonclinical result intact. The software therefore needs more context than a folder of documents sorted by upload date.

Use a source register that distinguishes the data cutoff, document issue date, approval state, study and population, and relationship to earlier versions. A newly uploaded copy of an old report should not displace a later approved report. Equally, a newly available safety communication needs assessment even if it falls after the planned drafting cutoff.

The regulatory basis matters. ICH E6(R3), final version adopted January 6, 2025, recommends at least annual IB review and revision when necessary under sponsor procedures. More frequent revision may be appropriate as relevant information emerges; some information warrants communication before inclusion in a revised IB. The same section allows appropriate alternative product information where authorities permit it. This is not a universal requirement to issue a new brochure exactly every twelve months. See Appendix A.1.1.

For US planning, FDA's September 2025 E6(R3) final guidance contains nonbinding recommendations. Have regulatory colleagues map the applicable requirements and sponsor procedures to each trial; a software calendar cannot establish that applicability.

The review and update passages were also checked against the consolidated E6(R3) text carrying June 16, 2026 corrections, Appendix A.1.1. That newer document should not be confused with a universal effective date: EMA lists its consolidated version as effective January 15, 2027, while its Principles and Annex 1 version is already effective.

ICH also calls for medically qualified involvement and approval by the disciplines that generated the data. It identifies reference safety information, or RSI, as relevant to expectedness assessment for expedited reporting. See Appendix A.1.2. Accordingly, design separate decisions for editing descriptive text, assessing a safety change, and authorizing any RSI change. An AI-generated paragraph should not collapse those decisions into one approval button.

Use the clinical protocol writing evaluation when an IB update and protocol change depend on the same new evidence.

How the candidates differ

The Otium DocWriter alternatives guide examines contributor review and structured-authoring scope in more detail.

Assyro: evaluate the document workflow, then prove IB-specific fit

Assyro is our first recommendation to evaluate when the IB forms part of a wider regulatory document workflow. Its document-management page describes a controlled repository with version history and tracked review and approval. That is relevant when the problem extends beyond drafting: writers need to know which document was approved and regulatory operations needs to identify the version used downstream.

The IB-specific condition is substantial. General regulatory authoring or document-management capability does not establish an available IB generator, automatic scientific impact analysis, or a complete investigator-distribution service. Those functions need their own evidence. This guide does not certify Assyro as a complete IB authoring replacement.

In an Assyro evaluation, start with a prior approved IB and the two source snapshots in the exercise below. Ask the team to show which steps occur in the application, which remain with your medical writer, and which require another system. Inspect the resulting document and review record together. If you require editable Word output, open the actual exported file in your supported Word environment and verify it; an editor demonstration is insufficient.

The practical reason to consider this approach is coordination with downstream document handling. Its potential cost is an additional authoring tool or manual source-impact process if those tasks are outside the agreed scope. Write that boundary into the proposal. If automated IB drafting from sponsor sources is a mandatory requirement and cannot be demonstrated, Assyro does not pass that purchase gate simply because it appears first here.

Otium Regulatory DocWriter: structured writing with your experts in control

Otium explicitly lists investigator brochures among the documents its Regulatory DocWriter helps set up. Its features page describes regulatory templates, graphs and tables, collaboration with reviewers and study experts, and an automatically created change log. These statements support evaluating it as a regulatory writing workspace. They do not establish automatic source synthesis or detection of contradictions across an entire IB.

That distinction can suit a team whose qualified writers will continue to interpret evidence and whose immediate problem is document setup and review coordination. Decide whether you are buying a better working environment or expecting the application to propose scientific updates. The second expectation requires additional proof.

Bring one section with a table, a supporting source, and an unresolved medical comment. Have two reviewers propose conflicting edits, then ask the writer to resolve them and create a release candidate. Check whether the final text, the disposition of each comment, and the reason for the change can be reconstructed. A list of edits may show what changed without explaining why the scientific interpretation was accepted.

Also inspect your actual sponsor template and required output. Confirm what customization, document migration, and reviewer access the quoted package includes. If your main acceptance criterion is automatic discovery of every statement affected by a new safety source, treat that as unverified until demonstrated. A writer-led update process can still be acceptable if it is explicit, repeatable, and included in your resourcing plan.

TraceDraft Medical Writing: section-level sources and evidence handoff

TraceDraft Medical Writing, from Cybroscape Technologies, explicitly names IBs in its medical-writing workspace. The page describes templates with source-grounded prompts, section-level status and reviewer routing, and an evidence pack attached to export. That gives the buyer a specific authoring and review workflow to investigate rather than inferring IB support from a generic clinical-document claim.

Its evaluation should focus on the relationship between sections and their sources. For example, if a clinical section uses the latest safety table but the opening summary still relies on the previous table, can the reviewer see that disagreement? Section-level completion alone does not establish whole-document consistency.

Ask the vendor to export an IB section and its evidence pack, then give both to a colleague who did not attend the demo. Can that colleague locate the exact supporting table, identify its version and cutoff, and distinguish direct source content from the author's interpretation? Repeat after replacing the source. The answer determines whether the evidence pack is useful outside the authoring session.

TraceDraft belongs on the shortlist for a team seeking explicit IB scope with source-oriented section review. Confirm whether impact detection, full-document reconciliation, sponsor template configuration, and the required export format are included in the proposed module. Its public description does not resolve those boundaries. If the evidence pack depends on continued access to a vendor-hosted source link, agree how the record remains usable after contract termination or source withdrawal.

Skaldi: public-evidence drafting needs a sponsor-data challenge

Skaldi's official site explicitly advertises investigator-brochure first drafts. Its described starting inputs are the drug, indication, and objectives, followed by research across public sources. It also describes editing, version comparison, and DOCX/PDF export. This is a different starting point from asking writers to assemble an IB solely from a controlled sponsor source package.

Public evidence can help a reviewer locate relevant background, but it cannot establish the contents of an unpublished sponsor study. The decisive question is how the contracted workflow distinguishes your investigational product and evidence from related products, public labels, and literature. Do not infer that a public-source sample demonstrates your complete IB.

For a pilot, provide a fictional investigational-product code that is intentionally similar to a marketed product name. Include one approved sponsor fact that differs from the public comparator's characteristics. Ask the vendor to show the origin of each resulting statement and any unresolved product-identity question. A plausible sentence about the wrong formulation should fail the exercise even if its public citation is real.

Skaldi merits evaluation where public-evidence assembly is a material part of the drafting burden and the team can independently assess the resulting sources. Before using it for proprietary program updates, verify sponsor-data ingestion, isolation, source precedence, and scientific review. Request the full output and provenance record from the pilot. The public page's timing and regulatory-alignment claims are not a substitute for that evidence, and this guide does not adopt them as measured results.

A worked demonstration: the old safety statement must change

Use this fictional exercise to compare vendors. It is not patient data, a clinical recommendation, or a reported software result. The purpose is to test evidence handling, not to assess the safety of an actual product.

The sponsor is preparing IB edition 3 for investigational product Example-X. Edition 2 has a March 31 data cutoff. Its summary and Effects in Humans section both contain this statement:

“Through March 31, no serious adverse events were reported among the 24 participants exposed to Example-X in Study EX-01.”

The earlier statement is supported within that historical scope. For the new edition, the sponsor supplies a later approved cumulative safety summary. The new information contradicts any current claim that no serious adverse events have been reported, but it does not erase what was known at the earlier cutoff.

Round one: establish the baseline from a bounded source package

Give each vendor the same inputs. For this exercise, all documents and figures below are invented.

Ask the vendor to prepare a draft summary and Effects in Humans section, attach their supporting sources, and export a review copy. Check the qualifier “through March 31.” If the draft silently turns a time-bounded statement into “Example-X has no serious adverse events,” it has already failed the source-scope test.

Save the output and evidence record before the next round. Without a baseline, you cannot distinguish a genuine update from an entirely regenerated document that happens to read differently.

Round two: introduce contradictory evidence and an ambiguous file

Now provide SAF-02, an approved cumulative summary through June 30. It includes the original 24 participants and 16 additional exposed participants, for 40 unique exposed participants. It reports two serious adverse events in two participants, with causality assessment unresolved in the supplied summary.

Also add SAF-draft, an unapproved file uploaded later than SAF-02. It contains no explicit cutoff and an unlabeled value “2” beside a safety-event heading. The vendor should neither prefer it because of upload time nor guess whether “2” means events, participants, or a severity grade.

The requested new draft sentence is deliberately restrained:

“Through June 30, two serious adverse events were reported in two of the 40 participants exposed to Example-X in Study EX-01. Causality assessment was unresolved in the supplied approved safety summary.”

That is an illustrative expected draft, subject to scientific review. It does not establish relatedness, an adverse-reaction frequency, a monitoring change, or an RSI decision. The denominator remains 40: adding the earlier 24 would double-count participants already included in the cumulative update.

Inspect every affected location and preserve the decision

Updating the Effects in Humans paragraph alone is insufficient if the opening summary retains an unqualified zero-event claim. Use this change record during the demo:

The old sentence may remain in a clearly identified historical account. The failure is presenting it as the current conclusion, or leaving readers to reconcile contradictory current statements themselves.

Finally, introduce a safety communication received after the June 30 cutoff. Ask the team to record when it arrived, who assessed it, and whether it changes the revision plan or requires a separate communication. Do not accept either silent incorporation into a supposedly frozen source package or automatic exclusion because it arrived late. The exercise should leave an explicit assessment and disposition, with the approved cutoff preserved or deliberately changed. The responsible scientific and regulatory colleagues determine the action; the application records and supports it.

If a stale current safety statement survives during a pilot, retain the actual outputs and trace the failure. Was SAF-02 excluded at ingestion? Was its cutoff lost? Did drafting retrieve SAF-01? Did the impact review cover only one section? Did a later edit restore old text? These are diagnostic questions, not assumed causes. Correct the demonstrated failure point and repeat the same update before accepting the workflow.

Apply the medical-writing version-control exercise to keep the previous approved IB distinct from the revised draft and its new decision.

Scientific approval and distribution are separate acceptance gates

The authoring application does not have to perform every downstream task, but the handoffs need named owners. Decide where scientific approval occurs, where the released IB becomes authoritative, and how the approved version reaches its intended recipients.

For scientific review, assign sections to the relevant disciplines and record who resolves disagreements. A pharmacology reviewer may identify a dose-description problem that affects the clinical summary. The workflow should make that dependency visible even if the assigned writer performs the correction manually. Closing a comment should not silently authorize a change outside the reviewer's responsibility.

For release, inspect the actual exported artifact. Confirm its edition, approval state, dates, tables, references, and complete text against the approved source version. Then check what accompanies it: a clean document for recipients, any required comparison copy, source register, and retained review decisions. Specify which records are internal; a detailed authoring evidence pack is not automatically the package intended for investigators.

Distribution may occur in another system. Make the handoff concrete by recording the released edition, intended trial/site or recipient group, distribution date, and any acknowledgment your process requires. Ask who can identify outstanding recipients and correct an accidental distribution of the superseded edition. Do not assume that an author's version history proves receipt by an investigator.

A procurement record you can take into the pilot

Record pass, fail, or unresolved for each item, alongside the actual evidence and its owner. Treat a failed mandatory item as a purchase blocker. A missing demonstration stays unresolved rather than receiving partial credit for a roadmap promise.

Include both initial drafting and a later revision in the commercial scope. Ask vendors to separate software fees from template setup, source preparation, onboarding, external-reviewer access, validation support, and any managed writing service. Confirm whether a revision consumes another document allowance and whether export or archival access incurs additional charges. This guide does not supply invented vendor prices.

Also assign the work the software leaves to your team. A proposal with a lower license fee may require more manual source reconciliation; that may be acceptable if the work is visible and staffed. Measure reviewer effort during the same pilot, including corrections and evidence retrieval. First-draft generation time alone omits much of the work you are buying software to support.

Choose by the requirement that cannot fail

Start with Assyro when controlled documents and the broader regulatory workflow are central, conditional on demonstrating the required IB tasks. Compare Otium when your writers will own scientific interpretation and need a structured writing environment. Include TraceDraft Medical Writing when explicit IB scope, section-level source work, and an exportable evidence package match the task. Evaluate Skaldi when public-evidence assembly matters, with a separate gate for proprietary sponsor evidence and product identity.

If an updated safety source cannot reliably reach every affected current statement, none of the attractive secondary features resolves that failed requirement. Choose a narrower, explicitly controlled workflow or continue evaluation until the gap is closed.

Bring the source register and two-round exercise to an Assyro document-management demonstration, and use the same acceptance record with every alternative. Request the new draft, its change record, and the prior approved edition together. Those artifacts make the buying decision reviewable.

Use Assyro’s regulatory-writing overview to scope an IB evaluation; an authoring workflow does not establish scientific approval or distribution.